MARKET

ALIM

ALIM

Alimera Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.590
-0.020
-0.43%
Closed 16:00 10/20 EDT
OPEN
4.620
PREV CLOSE
4.610
HIGH
4.640
LOW
4.550
VOLUME
15.12K
TURNOVER
--
52 WEEK HIGH
9.98
52 WEEK LOW
0.0045
MARKET CAP
23.10M
P/E (TTM)
-3.5084
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress
ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal
GlobeNewswire · 09/23 13:00
Alimera Sciences Announces Multiple Posters And Papers Highlighting Durability Of ILUVIEN To Be Presented At EURETINA 2020 Virtual Congress
ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal
Benzinga · 09/23 12:05
Alimera Sciences Signs Distribution Agreement With Medis Pharmaceutical to Commercialize Iluvien® in Austria and the Czech Republic
GlobeNewswire · 09/15 13:00
Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020
ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, today announces that Rick Eiswirth, President and Chief Executive Officer, will present
GlobeNewswire · 09/09 13:00
Alimera Sciences Obtains Reimbursement Approval for ILUVIEN® Use in Non-Infectious Posterior Uveitis in Scotland
Continued execution on strategy to grow international sales of ILUVIEN with new territory approvals, expanded reimbursement of posterior uveitis, and further market penetrationATLANTA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes
GlobeNewswire · 09/08 13:00
Alimera Sciences Obtains Reimbursement Approval For ILUVIEN Use In Non-Infectious Posterior Uveitis In Scotland
Alimera Sciences Obtains Reimbursement Approval for ILUVIEN® Use in Non-Infectious Posterior Uveitis in Scotland ATLANTA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a
Benzinga · 09/08 12:15
Spero's (SPRO) IND Accepted by FDA for Pulmonary Disease Drug
The FDA accepts Spero's (SPRO) IND for SPR720 in development for the treatment of nontuberculous mycobacterial pulmonary disease.
Zacks · 09/01 15:10
Alimera Sciences Announces Enrollment of First Patient in Landmark NEW DAY Clinical Trial to Evaluate ILUVIEN® as Baseline Therapy for Diabetic Macular Edema
ATLANTA, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces that it has enrolled the first
GlobeNewswire · 09/01 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALIM. Analyze the recent business situations of Alimera Sciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALIM stock price target is 13.50 with a high estimate of 18.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 51
Institutional Holdings: 36.65M
% Owned: 728.40%
Shares Outstanding: 5.03M
TypeInstitutionsShares
Increased
4
17.59K
New
4
-64.36K
Decreased
2
6.14K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.02%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Non-Executive Chairman
C. Daniel Myers
President/Chief Executive Officer/Director
Richard Eiswirth
Chief Financial Officer
Phil Jones
Chief Operating Officer/Senior Vice President
Philip Ashman
Senior Vice President/Chief Marketing Officer
David Holland
Other
Samer Kaba
Lead Director/Independent Director
James Largent
Independent Director
Brian Halak
Independent Director
Garheng Kong
Independent Director
Peter Pizzo
Independent Director
John Snisarenko
Independent Director
Mary Szela
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALIM
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through U.S. and International segment. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, Canada, Lebanon and the United Arab Emirates, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Alimera Sciences Inc stock information, including NASDAQ:ALIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALIM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALIM stock methods without spending real money on the virtual paper trading platform.